4.5 Article

CCL2-driven inflammation increases mammary gland stromal density and cancer susceptibility in a transgenic mouse model

Journal

BREAST CANCER RESEARCH
Volume 19, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s13058-016-0796-z

Keywords

Mammary gland; Development; Macrophage; Chemokine (C-C motif) ligand 2; Mouse model; Mammographic density

Categories

Funding

  1. Australian National Breast Cancer Foundation (NBCF)
  2. Hospital Research Foundation (THRF)
  3. Victorian Breast Cancer Research Consortium
  4. St. Vincent's Hospital Research Endowment Fund
  5. University of Melbourne
  6. Wellcome Trust [101067/Z/13/Z]
  7. Medical Research Council Centre for Reproductive Health [G1002033]
  8. NIH [RO1 CA172451]
  9. University of Adelaide
  10. Florey Medical Research Foundation
  11. Australian Postgraduate Awards scholarship
  12. NBCF
  13. MRC [G1002033, MR/N022556/1] Funding Source: UKRI
  14. Medical Research Council [MR/N022556/1, G1002033] Funding Source: researchfish
  15. National Breast Cancer Foundation [ECF-11-06, CG-10-04] Funding Source: researchfish
  16. The Hospital Research Foundation [RF2011/2, RF2011/1] Funding Source: researchfish
  17. Wellcome Trust [101067/Z/13/Z] Funding Source: researchfish

Ask authors/readers for more resources

Background: Macrophages play diverse roles in mammary gland development and breast cancer. CC-chemokine ligand 2 (CCL2) is an inflammatory cytokine that recruits macrophages to sites of injury. Although CCL2 has been detected in human and mouse mammary epithelium, its role in regulating mammary gland development and cancer risk has not been explored. Methods: Transgenic mice were generated wherein CCL2 is driven by the mammary epithelial cell-specific mouse mammary tumour virus 206 (MMTV) promoter. Estrous cycles were tracked in adult transgenic and non-transgenic FVB mice, and mammary glands collected at the four different stages of the cycle. Dissected mammary glands were assessed for cyclical morphological changes, proliferation and apoptosis of epithelium, macrophage abundance and collagen deposition, and mRNA encoding matrix remodelling enzymes. Another cohort of control and transgenic mice received carcinogen 7,12-Dimethylbenz(a) anthracene (DMBA) and tumour development was monitored weekly. CCL2 protein was also quantified in paired samples of human breast tissue with high and low mammographic density. Results: Overexpression of CCL2 in the mammary epithelium resulted in an increased number of macrophages, increased density of stroma and collagen and elevated mRNA encoding matrix remodelling enzymes lysyl oxidase (LOX) and tissue inhibitor of matrix metalloproteinases (TIMP) 3 compared to non-transgenic controls. Transgenic mice also exhibited increased susceptibility to development of DMBA-induced mammary tumours. In a paired sample cohort of human breast tissue, abundance of epithelial-cell-associated CCL2 was higher in breast tissue of high mammographic density compared to tissue of low mammographic density. Conclusions: Constitutive expression of CCL2 by the mouse mammary epithelium induces a state of low level chronic inflammation that increases stromal density and elevates cancer risk. We propose that CCL2-driven inflammation contributes to the increased risk of breast cancer observed in women with high mammographic density.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available